Blood test for tumor DNA in high-risk B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a specific type of B-cell lymphoma that is considered high-risk for spreading to the brain or spinal cord.
- You are planning to start standard chemotherapy plus immunotherapy (like R-CHOP) for this lymphoma.
- You have not had any prior treatment for this aggressive lymphoma, except for up to 7 days of steroids.
- You are able to have a lumbar puncture (spinal tap) safely.
- You do not have other active cancers or serious infections that would interfere with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.